Article

bizjournals.com on 2022-01-10 18:10

Biogen defends Alzheimer's drug, highlights pipeline at J.P. Morgan conference

Related news

How will tax reform affect Biogen? Its CFO offered a few hints at J.P. Morgan bizjournals.com
MLam Research stock gains after J.P. Morgan defends bullish rating marketwatch.com
MCisco stock gains after J.P. Morgan defends bullish rating, says shares look attractive relative to peers marketwatch.com
Kollmann joins J.P. Morgan journalrecord.com
Tulsa
Target Corp oversold – J.P. Morgan business.financialpost.com
Biogen trial drug shows promise in fight against Alzheimer's The Japan Times
Arizona , Phoenix , Switzerland , United States
Biogen pays California biotech $350M upfront for Alzheimer's gene therapy bizjournals.com
California
WAlzheimer's drug from Biogen, partner receives FDA approval wraltechwire.com
Cambridge , Japan
Biogen analysts pounce on 'thin' Alzheimer's trial data bizjournals.com
Biogen says new drug shows promise in combating Alzheimer's metro.us
Biogen shares soar as FDA reviewers support Alzheimer's drug Sydney Morning Herald
Wall Street , Massachusetts , Cambridge
Biogen buoyed despite Alzheimer's drug's new, more restrictive label bizjournals.com
Biogen to cease production of controversial Alzheimer's drug POLITICO
Biogen doubles down on Alzheimer's with new collaboration deal bizjournals.com
Biogen touts ‘resilience’ but gives little guidance on Alzheimer's drug bizjournals.com
Biogen lays out plans for confirmatory study of Alzheimer's drug bizjournals.com
Biogen reworks Alzheimer's drug pacts in bullish move bizjournals.com
Biogen stock gains on leaked Alzheimer's drug data bizjournals.com
San Diego
In reversal, Biogen to file for approval of Alzheimer's drug bizjournals.com